

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



Research in Diagnostic and Interventional Imaging

journal homepage: https://www.journals.elsevier.com/redii



# Original article

# Investigating of the role of CT scan for cancer patients during the first wave of COVID-19 pandemic



Sylvain Bourdoncle<sup>a</sup>, Thomas Eche<sup>a</sup>, Jeremy McGale<sup>b</sup>, Kevin Yiu<sup>b</sup>, Ephraïm Partouche<sup>a</sup>, Randy Yeh<sup>c</sup>, Samy Ammari<sup>d,e</sup>, Hervé Rousseau<sup>a</sup>, Laurent Dercle<sup>f,\*</sup>, Fatima-Zohra Mokrane<sup>a,\*</sup>

<sup>a</sup> Radiology Department, Rangueil University Hospital, 1 avenue du Professeur Jean, Poulhes, 31059, Toulouse France

<sup>b</sup> Columbia University Vagellos College of Physicians and Surgeons, Department of Radiology, New York, New York City, USA. Department of Radiology New York

Presbyterian Hospital, United States

<sup>c</sup> Memorial Sloan Kettering Cancer Center, Molecular Imaging and Therapy Service. New York, United States

<sup>d</sup> Département de l'Imagerie Médicale, Service d'Imagerie Diagnostique, Gustave Roussy, Université Paris Saclay, Villejuif, France

<sup>e</sup> BIOMAPS. UMR1281. INSERM.CEA.CNRS.Université Paris-Saclay, France

<sup>f</sup> Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States

ARTICLE INFO

Article History: Received 25 October 2021 Accepted 21 March 2022 Available online 31 March 2022

### 1. Introduction

The COVID-19 pandemic has dramatically changed medical, economic, and social practices worldwide. In early 2020, the virus spread quickly around the globe, rapidly contributing to the largest pandemic outbreak since the great influenza crises of 1918 and 2009 [1]. This pandemic has had a disproportionate impact on healthcare systems, both directly by overloading hospitals with COVID patients and indirectly by modifying how unaffected patients-those without an active COVID infection-are managed. While these consequences have been sparsely investigated in pediatric [2] and pregnant [3] populations, there is an overall paucity of research in this area and many studies are burdened by limitations such as the use of purely retrospective patient cohorts. Moreover, there are even fewer studies evaluating the lasting effects of the pandemic on cancer patients specifically [4], despite the fact that cancer remains a leading cause of death worldwide. As cancer treatments continue to improve, and the population of "chronic" oncologic patients grows, it will be of utmost importance to improve detection of emergent diseases in the setting of pre-existing cancer.

With COVID-19, as with many diseases of the 21st century, there exists a central role for imaging in diagnosis, management, and prognostication. Chest Computed Tomography (CT), in particular, has demonstrated potential clinical utility due to its accessibility, speed, and relatively high diagnostic sensitivity for COVID-19 detection, ranging from 61% [5] to 99% [6]. Specificity is also promising, though a bit more controversial, with recent studies indicating performances up to 91% [7], dramatically improved from older publications

hovering around 25% [8]. It is important to note that these metrics are achieved in the absence of underlying disease, in patients with a presumed "normal" pre-infection CT appearance of pulmonary parenchyma. In theory, pre-existing parenchymal abnormalities, like those widely observed in cancer patients, or related drug-induced pulmonary changes, may compromise the performance of chest CT in diagnosing active COVID-19 infection. However, how exactly this underlying disease impacts imaging performance is yet to be fully explored, and thus the applicability of diagnostic chest CT remains disputed [9, 10] and seen less favorably than the gold standard of RT-PCR. The main objective of the present study, conducted during the first wave of the COVID-19 pandemic, is to perform a systematic review and meta-analysis comparing the performance of chest CT for the diagnosis of COVID-19 in patient populations with and without cancer.

# 2. Materials and methods

# 2.1. Study selection and literature search strategy

The study protocol was developed and previously registered in PROSPERO with the following registration number CRD42020184819.

For our purposes, a systematic search of the major reference database MEDLINE (PubMed), was undertaken in April 2020. Two major imaging databases built for the COVID-19 pandemic, Radiology [11] and European Radiology [12], were also included in the search. The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Key search terms included "CT" AND "COVID-19". Details of search terms used for each database are reported in Table 1. All articles from 01/

2772-6525/© 2022 The Authors. Published by Elsevier Masson SAS on behalf of Société française de radiologie. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

<sup>\*</sup> Corresponding authors:

https://doi.org/10.1016/j.redii.2022.100004

## Table 1

Keywords	("CT findings" OR "CT scan" OR "CT-scan") AND ("COVID-
	19"OR "COVID19" OR "COVID 19")
Publication period	01/02/20 - 04/23/20

02/2020 to 04/23/2020 were screened. After removal of duplicate articles and publications including only an abstract, we automatically excluded reports that were not in English or that were non-human studies, case reports with less than 5 patients, systematic or non-systematic reviews, comments, correspondences, editorials, guidelines, and meta-analyses. The commercial bibliographic management software used was EndNote X9.3.1.

## 2.2. Inclusion and exclusion criteria

Titles and abstracts of articles were initially screened to select eligible publications, and we removed those with the following characteristics: (1) Publications with data other than imaging; (2) Abstracts

General publication data	Title	
	Authors	
	Journal	
	Date of publication	
	Country	
Study design and characteristics	Retrospective study	
	Prospective study	
	Case report / ncase series	
	Editorial	
	Consensus conference	
	Correspondence / comment	
	Review / Meta-analysis	
	Monocentric	
	National multicentric	
	International multicentric	
Population	Percentage of oncologic patients	
	Specific population (pediatric – pregnant)	
Diagnostic performance	Sensitivity	
	Specificity	
	TP/FP/FN/TN	

Abbreviations: CT:computed tomography, TP: true positives, FP: false positives, FN: false negatives, TN: true negatives.




Fig. 1. PRISMA flowchart.

with unavailable full-text versions; (3) Studies investigating the diagnostic value of ultrasound (US), chest X-ray or other imaging modalities; (4) Studies focused on pregnant women or newborns.

All studies identified by the search were screened for eligibility by two independent authors (S.B and F.Z.M) blinded to each other's decisions. In case of disagreement, a consensus was reached by a third reviewer (E.P)

# 2.3. Data extraction

Two reviewers (S.B and F.Z.M) extracted the following data from each selected imaging-based article: (1) Authors, journal and year of publication, country of origin; (2) Study design characteristics; (3) Demographics as well as clinical and pathological variables with percentage of cancer patients if available; (4) Imaging performance metrics such as sensitivity, specificity, and contingency tables. Table 2 summarizes all extracted data. The two investigators (S.B, F.Z.M) assessed all studies independently. Disputes were discussed with a third reviewer (L.D) and resolved by consensus.

# 2.4. Data analysis

The sensitivity and specificity of chest CT were pooled separately using a random-effects model. The positive predictive value (PPV) and negative predictive value (NPV) of CT as a diagnostic test was estimated for a wide range of disease prevalence rates. Studies without extractable data were excluded from the meta-regression analysis. Sensitivity analysis was conducted for chest CT. Additionally, all duplicate studies were removed.

#### 2.5. Statistical analysis


Analyses were conducted using Microsoft Excel (v2019, Microsoft, USA, 2019) and open-source R software (version 3.6.2; R Foundation for Statistical Computing, Vienna, Austria). A p-value less than 0.05 was considered indicative of statistical significance ( $\alpha = 0.05$ ).

## 3. Results

#### 3.1. Identification and selection of studies

Our literature search resulted in 175 unique studies after removal of duplicates. Records that included only an abstract (n = 5), were non-English and did not have extractable imaging data (n = 10), and those that had no imaging data at all (n = 22) were automatically excluded. We screened the remaining studies and removed case reports or series of less than 5 patients (n = 9), correspondences, comments, and editorials (n = 7), consensus conferences (n = 3), and reviews/meta-analyses (n = 13). In total, 106 publications fulfilled our search criteria and were fully reviewed. For our analysis of diagnostic accuracy, we further curated the studies under consideration. Of the 106 surveyed, 96 had extractable data for a two-by-two contingency table of diagnostic performance, but 30 of these were removed as they only reported the true-positive number of patients. Additionally, 13 studies that included fewer than 20 patients were removed to improve statistical significance, leaving 53 reports for our final analysis [3,5,6,8,13–61], (Supplementary table A). The PRISMA flowchart of literature search and study selection process is shown in Fig 1.

Among the publications identified for diagnostic accuracy evaluation, 92% (49/53) were retrospective studies, 4% (2/53) were case reports/case series with more than 5 patients, and only 4% (2/53) were prospective studies. Most of the reviewed works (n = 41/53, 77%) were monocentric and locally based. Moreover, only 23% (n = 12) were national multicenter studies and only one was multinational.



**Fig. 2.** ROC curve of chest CT for diagnosis of COVID-19., The pooled performance was estimated (black line). The pooled false positive rate is displayed as a function of pooled sensitivity (black line). The FPR and Se for each study are displayed (dots) as well as their estimated 95 confidence intervals (gray line).

#### 3.2. CT diagnostic performances

Of the 53 studies reviewed for diagnostic accuracy, 6 presented data on two different populations, allowing performance calculations to be carried out for each cohort individually. Overall, our analysis of chest CT sensitivity for the detection of COVID-19 pneumonia showed promising results: In 51% of cases (30/59), the sensitivity was found to be above 0.9, with varying confidence intervals (Fig 2). However, chest CT specificity remained low at just 0.565 (IC95 [0.539; 0.591]). In 93% of cases (55/59), a specificity lower than or equal to 0.5 was reported (Fig 3).

# 3.3. Oncologic population

Only 15 of the original 106 reports (14.2%) identified in our search discretely included cancer patients; 92 (86.8%) made no mention of cancer rates in their study populations and subsequently failed to demarcate these patients within the data, 1 study (0.9%) identified and excluded cancer patients while 13 (12.2%) indicated the presence of cancer in their cohorts but without further details. Finally, 3 studies (2.8%) pertained specifically to oncologic populations, but none were included in the final analysis due to only reporting true positives (n = 2) or outright lack of performance data (n = 1). Overall, only 7 studies that included and described cancer patients were included in the final analysis for chest CT performance. The aggregate prevalence of cancer across all studies surveyed was 0.3% (34/11,352 patients), with absolute numbers in individual reports ranging from 1 to 17 patients. Therefore, a specific analysis of chest CT performance in the oncologic population could not be done.

# **Forest plot**

			57	
Pan F2020	<b>⊢</b> ∎-1	0.82[0.63, 0.92	2] Pan F. 2020	⊢ I 0.50 [0.05, 0.95]
Long C2020	H	0.96 0.84. 0.99	Long $\overline{C}$ . 2020	HO 99[0.91, 1.00]
Chung M2020	<b>⊢</b> ∎-1	0.84 0.64, 0.94	Chung M. 2020	⊢ I 0.50 0.05, 0.95
Bernheim A2020	H	0.77 0.69, 0.84	Bernheim A. 202	0   0.50 0.05, 0.95
Li K2020	H	0.92[0.84, 0.96		⊢ I 0.50 [0.05, 0.95]
Zhao W2020	H	0.92[0.85, 0.9	Zhao W2020	⊢ I 0.50 [0.05, 0.95]
Ling Z2020	<b>H</b>	0.83 0.79, 0.8		0.50 0.05, 0.95
Ling Z2020	Ħ	0.88 0.84, 0.9	Ling Z2020	I 0.50[0.05, 0.95]
Ding X2020	⊢∎⊣	0.78 0.65, 0.8	Ding X2020	⊢ − − 1 0.50[0.05, 0.95]
Ding X2020	H	0.97[0.89, 0.9	Ding X2020	0.50 0.05, 0.95
Li Y2020	H	0.95 0.86, 0.98	Li Y2020	0.50 0.05, 0.95
Wang Y2020	H	0.84 0.73, 0.9	Wang Y2020	0.50 0.05, 0.95
Wang Y2020	H	0.98 0.92, 1.00	Wang Y2020	0.50 0.05, 0.95
Li K2020	HEH	0.72[0.61, 0.8	Li K2020	0.50 0.05, 0.95
Liang T2020	H	0.95 0.88, 0.98	Liang T2020	0.50 0.05, 0.95
Liang T. 2020	H	0.98 0.93, 1.00	Liang T2020	0.50[0.05, 0.95]
Bai H2020		0.94[0.90, 0.90	Bai H2020	■ 0.24[0.19, 0.30]
Bai H. 2020	H <b>H</b>	0.72 0.66, 0.78	Bai H2020	■ 0.98 0.89, 0.96
Ai T2020		0.96 0.95, 0.9	Ai T2020	■ 0.25 0.22, 0.30 ■ 0.50 0.05, 0.95
Li B2020	H-H	0.89 0.70, 0.9	Li B2020	0.50[0.05, 0.95]
Zhao W. 2020		0.93 0.87, 0.9	Zhao W2020	0.50 0.05, 0.95
Wu J2020		0.94 0.87, 0.9	Wu J2020	
Zhong Q2020		0.950.87, 0.98	Zhong Q2020	0.50 0.05, 0.95
Yang H2020	H	0.96 0.87, 0.9	Yang H2020	0.50 0.05, 0.95
Liu KC2020	, HI	0.95 0.88, 0.98		0.50 0.05, 0.95
Zhu W2020 Wang X. 2020	H-M	0.92 0.78, 0.98	Zhu W2020	⊢ 0.34[0.24, 0.44]
Ma YL. 2020		0.91 0.89, 0.9	Wang X2020	0.50 0.05, 0.95
Chen X. 2020	1-1-1	0.76 0.68, 0.8	Ma YL2020	
Xu YH. 2020	H	0.91 0.87, 0.98	Chen X2020	0.50[0.05, 0.95]
Caruso D. 2020	⊢ <b>=</b> +  ¶	0.81 0.69, 0.90	Xu YH2020	i 0.50[0.05, 0.95] i 0.57[0.47, 0.67]
Li L. 2020		0.89 0.83, 0.94	Caruso D2020	H■H 0.57[0.47, 0.67] ■ 0.96[0.93, 0.97]
Fang Y. 2020	Here .		Li L. 2020	
Xie X. 2020	년	0.97 0.88, 0.99	Fang Y. 2020	0.50[0.05, 0.95]
Wen Z. 2020		0.86 0.78, 0.9	Xie X2020	0.50[0.05, 0.95]
Chen A. 2020	⊦=-	0.910.79, 0.9	Wen Z2020	
Huang L. 2020	H	0.950.90, 0.98	Chen A. 2020	0.50[0.05, 0.95]
Inui S. 2020		0.600.51, 0.69	Huang L2020 Inui S. 2020	0.50[0.05, 0.95]
Ng MY. 2020		0.89[0.69, 0.9	Ng MY. 2020	0.50[0.05, 0.95]
Tabatabaei S. 2020		0.96 0.91, 0.98	Tabatabaei S. 202	
Dangis A. 2020		0.86 0.77, 0.9	Dangis A. 2020	0.50[0.05, 0.95]
Wang, D. 2020		0.67 0.31, 0.64	Wang, D. 2020	0.50[0.05, 0.95]
Qiu H. 2020		0.53 0.37, 0.68	Qiu H. 2020	0.50 0.05, 0.95
Lu X. 2020	Here I	0.65 0.58, 0.72	Lu X. 2020	0.500.05, 0.95
Zheng F. 2020	L	0.66 0.46, 0.8		0.50[0.05, 0.95]
Wang Y. 2020	'⊢∎-i'	0.96 0.54, 0.78	Wang Y. 2020	0.500.05, 0.95
Hu Z. 2020		0.70 0.50, 0.84		0.500.05, 0.95
Guan WJ_2020		0.86 0.84, 0.88	Guan WJ 2020	0.50[0.05, 0.95]
Yang W_2020	H	0.88 0.82, 0.93	Yang W 2020	0.50[0.05, 0.95]
Guan CS_2020	H-	0.88 0.77, 0.94	Guan CS 2020	i 0.50[0.05, 0.95]
Chen Z_2020	H	0.92 0.85, 0.90	Chen Z 2020	⊢ <b>–</b> 0 50[0.05. 0.95]
Xie X2020		0.960.91, 0.98	Xie X. 2020	0.50(0.05, 0.95) 0.50(0.05, 0.95) 0.50(0.05, 0.95) 0.50(0.05, 0.95)
Wang K_2020		0.960.91.0.98	Wang K 2020	I 0.5010.05, 0.951
Chen J_2020		0.97 0.95, 0.99	Chen J 2020	
Xu XW_2020	H	0.98 0.90, 0.99	2 Xu XW_2020	⊢− <b>−</b> − 0.50[0.05, 0.95]
Zhang JJ_2020		0.99[0.95, 1.00	Zhang JJ 2020	
Himoto Y_2020		0.43 0.22, 0.6	Himoto Y 2020	⊢ 0.94[0.60, 0.99]
Cheng Z_2020	<b>—</b>	0.96 0.70, 1.00	Cheng Z_2020	⊢ 0.27[0.14, 0.45]
Liu K_2020	H	0.84 0.77, 0.90	D] Liu K_2020	⊢ I 0.50[0.05, 0.95]
		- AL	17. STA	
E				
0.00	0.00			0.0E 0.76
0.22	2 0.80			0.05 0.76
5	Sensitivity			Specificity

**Forest plot** 

Fig. 3. Forest plots of sensitivity and specificity of chest CT for the diagnosis of COVID-19., The Sensitivity and Specificity for each study is displayed as well as their estimated 95 confidence interval.

# 4. Discussion

In this systematic review and meta-analysis on chest CT imaging for the diagnosis of COVID-19 pneumonia, performed from 01/02/ 2020 to 04/23/2020 with a special focus on oncologic populations, our main finding was that there exists a dearth of research specifically addressing cancer patients. Among the 53 articles included in our performance analysis, sensitivity of chest CT was 0.889, with a

low specificity of 0.565 (IC95 [0.539; 0.591]), falling below 0.5 in 90% of studies. Moreover, only 7 articles (7/53, 13%) specifically mentioned oncology patients in their results, rendering an evaluation of chest CT performance in this population impossible to conduct. The number of cancer patients in the individual studies included in our meta-analysis varied between 1 and 17 patients, for an aggregate total of 34 patients (0.3% of 11,352 patients included). Cancer prevalence in these cohorts was therefore much lower than the global

figure of 5.8% reported in WHO statistics [62]. Among all reviewed studies, only one (1/106, 1%) specifically reported performance in the cancer patient group, but unfortunately only reported true positive patients, precluding further analysis. Our results are consistent with existing literature which has confirmed the high sensitivity of CT for the diagnosis of COVID-19, ranging from 89.76% (CI95 [84.42%; 93.84%]) to 94.6% (CI95 [91.9%; 96.45%]) [63,64]. More recent literature, published after completion of our study, shows improved values for specificity ranging from 87.2% (CI95 [83.9%; 89.9%]) to 91% (CI95 [91%; 92%]) [7,65]. Of note, these studies do not detail the prevalence of cancer in their study populations.

Several challenges regarding cancer management have arisen in the era of COVID-19. Primarily, although still poorly defined, the incidence of COVID-19 appears to be almost doubled in oncology populations when compared to the general population [66,67], with cancer patients facing a higher risk of severe disease manifestation requiring invasive airway management. This problem is compounded by the relatively older age of cancer patients, as age correlates with a higher frequency of hospitalization and severe disease [66,67], and the increased likelihood of COVID-19 exposure associated with frequent hospital visits for disease monitoring and treatment [68]. Moreover, the immunocompromising nature of both cancer and the associated treatment may make patients more susceptible to infections, though this point remains controversial as the estimated probability of death in infected patients with cancer ranges broadly from 13% to 33.1% [69,70]. Some studies have even reported similar death rates between cancer and non-cancer groups [71]. Finally, as a result of the pandemic, the quality of oncological care may suffer due to cancelation or postponement of non-urgent procedures and examinations, with possible consequences for patients who are lost to follow-up. According to a survey by the American Cancer Society Cancer Action Network (ACSCAN) during the first wave of COVID-19, 27% of patients undergoing active cancer treatment reported an interruption of a care, of which one out of five was related to a follow-up imaging exam [72]. In light of these findings, it is clear that the principle dilemma for oncologists has been the prioritization of tests and follow-up, balancing risk and benefit in the context of the ongoing pandemic [73]. Recommendations by national and international societies can shed light on some of these difficult situations [74–76], and radiologists in particular may emerge as leading figures in pandemic management for oncology patients. The latter must learn to expertly recognize COVID-19 pneumonia, meet the expectations of each clinical contact, particularly in the context of oncology, and prioritize examinations according to individual cases. They must also be familiar with all possible differential diagnoses relating to a clinical situation and must be cognizant of the possibility for incidentalomas [77]. Above all, they must reorganize and adapt to the new proposed care pathway and create reports within the current medical landscape defined by COVID-19. This last piece may prove to be the most challenging, considering the torrent of often contradictory recommendations being published at an ever-increasing pace by national and international bodies.

The role of chest CT for the initial management of COVID-19 patients without underlying cancer is currently well established, guided by relatively homogenous international recommendations [78]. Although most patients now arrive at the emergency room with a positive PCR, the usefulness of CT remains steadfast, allowing for correction of possible false negatives, assistance in the construction of differential diagnoses, and orientation of patients with prognostic information [79]. The current study suffers from a few limitations. First, the date range of our survey only covers the first wave of pandemic. Since this time, and as described above, the role of CT has slowly evolved due to the improved availability of antigenic and PCR testing. In addition, it would be useful to have more information available about the specific cancer cases described in the literature, including the date of diagnosis, whether or not it was active disease,

and the treatment in progress. These additional pieces of data could be correlated with CT diagnostic performance. In conclusion, this meta-analysis highlights the lack of data concerning radiologic evaluation of COVID-19 cases in patients with underlying cancer. Further studies are required for this nuanced and highly sensitive population in order to better understand the specific performances of imaging techniques, and thereby lead to the improvement of disease management.

## **Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

# **CRediT authorship contribution statement**

Sylvain Bourdoncle: Investigation, Writing – original draft, Resources. Thomas Eche: Writing – review & editing, Resources. Jeremy McGale: Writing – review & editing. Kevin Yiu: Writing – review & editing. Ephraïm Partouche: Methodology, Writing – review & editing. Randy Yeh: Writing – review & editing, Resources. Samy Ammari: Writing – review & editing, Resources. Samy Ammari: Writing – review & editing, Resources. Hervé Rousseau: Validation. Laurent Dercle: Conceptualization, Methodology, Data curation, Software, Formal analysis, Writing – review & editing. Fatima-Zohra Mokrane: Conceptualization, Methodology, Supervision, Writing – review & editing.

## Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.redii.2022.100004.

#### Références

- [1] « WHO Coronavirus (COVID-19) Dashboard ». https://covid19.who.int
- [2] Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382(17):1663–5 23.
- [3] Yang H, Sun G, Tang F, Peng M, Gao Y, Peng J, et al. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. J Infect 2020;81(1): e40-4. doi: 10.1016/j.jinf.2020.04.003.
- [4] Desai A, Sachdeva S, Parekh T, Desal R. COVID-19 and Cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 2022 doi/full/10.1200/GO.20.00097.
- [5] Inui S, Fujikawa A, Jitsu M, Kunishima N, Watanabe S, Suzuki Y, et al. Chest CT Findings in Cases from the Cruise Ship "Diamond Princess" with Coronavirus Disease 2019 (COVID-19). Radiology 2020 Mar 17;2(2):e200110.
- [6] Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75 (7):1730–41.
- [7] Herpe G, Lederlin M, Naudin M, et al. Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France. Radiology 2021 Feb;298(2):E81–7 G. doi: 10.1148/ radiol.2020202568.
- [8] 7. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: a Report of 1014 Cases. Radiology 2020 Feb;26:200642. doi: 10.1148/radiol.2020200642.
- [9] ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. Available from: https://www.acr. org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection.
- [10] CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testingoverview.html
- [11] Radiology. COVID-19. Original research. https://pubs.rsna.org/2019-ncov\_articles.
- [12] European Radiology. Latest articles on COVID-19. https://www.european-radiology.org/highlights/covid-19.
- [13] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020 Jun;295(3):715–21. doi: 10.1148/radiol.2020200370.
- [14] Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol 2020 May;126:108961 doi: 10.1016/j.ejrad.2020.108961.
- [15] Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, Jacobi A, Li K, Li S, Shan H. CT imaging features of 2019 novel

coronavirus (2019-nCoV). Radiology 2020 Apr;295(1):202-7. doi: 10.1148/ radiol.2020200230.

- [16] Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li S, Shan H, Jacobi A, Chung M. Chest CT findings in Coronavirus Disease-19 (COVID-19): relationship to duration of infection. Radiology 2020 Jun;295 (3):200463. doi: 10.1148/radiol.2020200463.
- [17] Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C. The clinical and chest CT features associated with severe and critical COVID-19 Pneumonia. Invest Radiol. 2020 Jun;55(6):327–31. doi: 10.1097/RLI.00000000000672.
- [18] Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) Pneumonia: a multicenter study. AJR Am J Roentgenol 2020 May;214(5):1072-1077. doi: 10.2214/ AJR.20.22976.
- [19] Ling Z, Xu X, Gan Q, Zhang L, Luo L, Tang X, Liu J. Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol 2020 May;126:108956. doi: 10.1016/j.ejrad.2020.108956.
- [20] Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur J Radiol 2020 Jun;127:109009. doi: 10.1016/j. ejrad.2020.109009.
- [21] LI Y, Xia L. Coronavirus Disease 2019 (COVID-19): role of Chest CT in diagnosis and management. AJR Am J Roentgenol 2020 Jun;214(6):1280-1286. doi: 10.2214/AJR.20.22954.
- [22] Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, Shi H, Zhou M. Temporal changes of CT findings in 90 patients with COVID-19 Pneumonia: a longitudinal study. Radiology 2020 Aug;296(2):E55–64. doi: 10.1148/radiol.2020200843.
- [23] Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, Liu X, Huang M, Liao Y, Li S. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol 2020 Aug;30(8):4407–16. doi: 10.1007/s00330-020-06817-6.
- [24] Liang T, Liu Z, Wu CC, Jin C, Zhao H, Wang Y, Wang Z, Li F, Zhou J, Cai S, Liang Y, Zhou H, Wang X, Ren Z, Yang J. Evolution of CT findings in patients with mild COVID-19 pneumonia. Eur Radiol 2020 Sep;30(9):4865–73. doi: 10.1007/s00330-020-06823-8.
- [25] Bai HX, et al. Performance of radiologists in differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at chest CT. Radiology 2020;296(2):E46-E54. doi: 10.1148/radiol.2020200823.
- [26] Li B, Shen J, Li L, Yu C. Radiographic and clinical features of children with Coronavirus Disease (COVID-19) Pneumonia. Indian Pediatr 2020 May;57(5):423-426.
- [27] Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. Theranostics 2020;10(10):4606-4613. doi: 10.7150/thno.45016.
- [28] Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, Huang H, Li C. Chest CT findings in patients with Coronavirus Disease 2019 and its relationship with clinical features. Invest Radiol 2020 May;55(5):257–61. doi: 10.1097/RLI.00000000000670.
- [29] Zhong Q, Li Z, Shen X, Xu K, Shen Y, Fang Q, Chen F, Liang T. [CT imaging features of patients with different clinical types of coronavirus disease 2019 (COVID-19)]. Zhejiang Da Xue Xue Bao Yi Xue Ban. Chinese 2020 May 25;49(1):198–202. doi: 10.3785/j.issn.1008-9292.2020.03.05.
- [30] Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, Wei W. CT manifestations of coronavirus disease-2019: a retrospective analysis of 73 cases by disease severity. Eur J Radiol 2020 May;126:108941. doi: 10.1016/j.ejrad.2020.108941.
- [31] Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol 2020 Sep;92(9):1525-1532. doi: 10.1002/jmv.25763.
- [32] Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, Ge L, Wang F, Chen Q, Zhang Y, Zhao Q. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect 2020 Aug;26 (8):1063–8. doi: 10.1016/j.cmi.2020.03.032.
- [33] Ma YL, Xia SY, Wang M, Zhang SM, WH DU, Chen Q. Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases. Zhongguo Dang Dai Er Ke Za Zhi. Chinese 2020 Apr;22(4):290–3. doi: 10.7499/j.issn.1008-8830.2003016.
- [34] Chen X, Tang Y, Mo Y, Li S, Lin D, Yang Z, Yang Z, Sun H, Qiu J, Liao Y, Xiao J, Chen X, Wu X, Wu R, Dai Z. A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study. Eur Radiol 2020 Sep;30(9):4893–902. doi: 10.1007/s00330-020-06829-2.
- [35] Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, Dong L, Ma X, Zhang HJ, Gao BL. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020 Apr;80(4):394–400. doi: 10.1016/j. jinf.2020.02.017.
- [36] Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, Guido G, Bracci B, De Dominicis C, Laghi A. Chest CT features of COVID-19 in Rome, Italy. Radiology. 2020 Aug;296(2):E79–85. doi: 10.1148/radiol.2020201237.
- [37] Li L, Qin L, Xu Z, Yin Y, Wang X, Kong B, Bai J, Lu Y, Fang Z, Song Q, Cao K, Liu D, Wang G, Xu Q, Fang X, Zhang S, Xia J, Xia J. Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary ct: evaluation of the diagnostic accuracy. Radiology 2020 Aug;296(2):E65–71. doi: 10.1148/radiol.2020200905.
- [38] Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of Chest CT for COVID-19: comparison to RT-PCR. Radiology 2020 Aug;296(2):E115–7. doi: 10.1148/radiol.2020200432.
- [39] Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical Coronavirus Disease 2019 (COVID-19) Pneumonia: relationship to negative RT-PCR testing. Radiology 2020 Aug;296(2):E41–5. doi: 10.1148/radiol.2020200343.
- [40] Wen Z, Chi Y, Zhang L, Liu H, Du K, Li Z, Chen J, Cheng L, Wang D. Coronavirus disease 2019: initial detection on chest CT in a retrospective multicenter study of

103 Chinese patients. Radiol Cardiothorac Imaging 2020 Apr 6;2(2):e200092. doi: 10.1148/ryct.2020200092.

- [41] Chen A, Huang JX, Liao Y, Liu Z, Chen D, Yang C, Yang RM, Wei X. Differences in clinical and imaging presentation of pediatric patients with COVID-19 in comparison with adults. Radiol Cardiothorac Imaging 2020 Apr 6;2(2):e200117. doi: 10.1148/ryct.2020200117.
- [42] Huang L, Han R, Ai T, Yu P, Kang H, Tao Q, Xia L. Serial quantitative chest CT assessment of COVID-19: a deep learning approach. Radiol Cardiothorac Imaging 2020 Mar 30;2(2):e200075. doi: 10.1148/ryct.2020200075.
- [43] Ng MY, Lee EYP, Yang J, Yang F, Li X, Wang H, Lui MM, Lo CS, Leung B, Khong PL, Hui CK, Yuen KY, Kuo MD. Imaging Profile of the COVID-19 Infection: radiologic Findings and Literature Review. Radiol Cardiothorac Imaging 2020 Feb 13;2(1): e200034. doi: 10.1148/ryct.2020200034.
- [44] Tabatabaei SMH, Talari H, Moghaddas F, Rajebi H. CT features and short-term prognosis of COVID-19 Pneumonia: a single-center study from Kashan, Iran. Radiol Cardiothorac Imaging 2020 Apr 20;2(2):e200130. doi: 10.1148/ ryct.2020200130.
- [45] Dangis A, Gieraerts C, De Bruecker Y, Janssen L, Valgaeren H, Obbels D, Gillis M, Van Ranst M, Frans J, Demeyere A, Symons R. Accuracy and reproducibility of low-dose submillisievert chest CT for the diagnosis of COVID-19. Radiol Cardiothorac Imaging 2020 Apr 21;2(2):e200196. doi: 10.1148/ryct.2020200196.
- [46] Wang D, Ju XL, Xie F, Lu Y, Li FY, Huang HH, Fang XL, Li YJ, Wang JY, Yi B, Yue JX, Wang J, Wang LX, Li B, Wang Y, Qiu BP, Zhou ZY, Li KL, Sun JH, Liu XG, Li GD, Wang YJ, Cao AH, Chen YN. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China. Zhonghua Er Ke Za Zhi. Chinese 2020 Apr 2;58(4):269–74. doi: 10.3760/cma.j. cn112140-2020225-00138.
- [47] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020 Jun;20(6):689–96. doi: 10.1016/S1473-3099(20)30198-5.
- [48] Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK. Chinese pediatric novel coronavirus study team. SARS-CoV-2 infection in children. N Engl J Med 2020 Apr 23;382(17):1663–5. doi: 10.1056/NEIMc2005073.
- [49] Zheng F, Liao C, Fan QH, Chen HB, Zhao XG, Xie ZG, Li XL, Chen CX, Lu XX, Liu ZS, Lu W, Chen CB, Jiao R, Zhang AM, Wang JT, Ding XW, Zeng YG, Cheng LP, Huang QF, Wu J, Luo XC, Wang ZJ, Zhong YY, Bai Y, Wu XY, Jin RM. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci 2020 Apr;40(2):275–80. doi: 10.1007/s11596-020-2172-6.
- [50] Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China. J Infect Dis. 2020 May 11;221(11):1770–4. doi: 10.1093/infdis/jiaa119.
- [51] Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y, Shen H. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706–11. doi: 10.1007/s11427-020-1661-4.
- [52] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CO, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Apr 30;382(18):1708–20. doi: 10.1056/NEJMoa2002032.
- [53] Yang W, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016.
- [54] Guan CS, Lv ZB, Yan S, Du YN, Chen H, Wei LG, Xie RM, Chen BD. Imaging features of coronavirus disease 2019 (COVID-19): evaluation on thin-section CT. Acad Radiol 2020 May;27(5):609–13. doi: 10.1016/j.acra.2020.03.002.
- [55] Chen Z, Fan H, Cai J, Li Y, Wu B, Hou Y, Xu S, Zhou F, Liu Y, Xuan W, Hu H, Sun J. High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages. Eur J Radiol 2020 May;126:108972. doi: 10.1016/j. ejrad.2020.
- [56] Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. Clin Radiol 2020 May;75(5):341–7. doi: 10.1016/j.crad.2020.03.004.
- [57] Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020 May;80(5):e1–6. doi: 10.1016/j.jinf.2020.03.004.
- [58] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606.
- [59] Himoto Y, Sakata A, Kirita M, Hiroi T, Kobayashi KI, Kubo K, Kim H, Nishimoto A, Maeda C, Kawamura A, Komiya N, Umeoka S. Diagnostic performance of chest CT to differentiate COVID-19 pneumonia in non-high-epidemic area in Japan. Jpn J Radiol 2020 May;38(5):400–6. doi: 10.1007/s11604-020-00958-w.
- [60] Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, Yang W. Clinical features and chest CT manifestations of Coronavirus Disease 2019 (COVID-19) in a single-center study in Shanghai, China. AJR Am J Roentgenol 2020 Jul;215(1):121-6. doi: 10.2214/ AJR.20.22959.
- [61] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary

hospitals in Hubei Province. Chin Med J (Engl) 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.00000000000744.

[62] World Health Organization. Cancer Today. 2020. http://gco.iarc.fr/today/home.

- [63] Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Systematic review and meta-analysis on the value of chest CT in the diagnosis of Coronavirus Disease (COVID-19): sol scientiae, illustra Nos. Am J Roentgenol 2022. doi: 10.2214/AJR.20.23391.
- [64] Bao C, Liu X, Zhang H, BSC, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: a systematic review and meta-analysis. J Am Coll Radiol 2020 Jun; 17 (6):701–9. doi: 10.1016/j.jacr.2020.03.006.
- [65] Lieveld AWE, Azijli K, Teunissen BP, van Haaften RM, Kootte RS, van den Berk IAH, van der Horst SFB, de Gans C, van de Ven PM, Nanayakkara PWB. Chest CT in COVID-19 at the ED: validation of the COVID-19 Reporting and Data System (CO-RADS) and CT severity score: a prospective, multicenter, observational study. Chest 2021 Mar;159(3):1126-35. doi: 10.1016/j.chest.2020.11.026.
- [66] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6.
- [67] Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894–901. doi: 10.1016/j. annonc.2020.03.296.
- [68] Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020;6(7):1108–10. doi: 10.1001/jamaoncol.2020.0980.
- [69] Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes Jr G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020 Jun 20;395 (10241):1907–18. doi: 10.1016/S0140-6736(20)31187-9.

- [70] de Melo AC, Thuler LCS, da Silva JL, et al. Cancer inpatients with COVID-19: a report from the Brazilian National Cancer Institute. PLoS ONE 2020;15(10): e0241261 Published 2020 Oct 26. doi: 10.1371/journal.pone.0241261.
- [71] Aboueshia M, Hussein MH, Attia AS, et al. Cancer and COVID-19: analysis of patient outcomes. Future Oncol 2021;17(26):3499–510. doi: 10.2217/fon-2021-0121.
- [72] COVID-19 Pandemic Early Effects on Cancer Patients and Survivors: April 2020. American Cancer Society Cancer Action Network. 2020. https://www.fightcancer. org/policy-resources/covid-19-pandemic-early-effects-cancer-patients-and-survivors-april-2020.
- [73] Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020;17 (5):268–70. doi: 10.1038/s41571-020-0362-6.
- [74] Tagliaferri L, Di Stefani A, Schinzari G, Fionda B, Rossi E, Del Regno L, et al. Skin cancer triage and management during COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020 Jun;34(6):1136–9.
- [75] Schultz P, Morvan J-B, Fakhry N, Morinière S, Vergez S, Lacroix C, et al. French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic. Eur Ann Otorhinolaryngol Head Neck Dis 2020 May;137(3):167–9. doi: 10.1016/j.anorl.2020.04.006.
- [76] Akladios C, Azais H, Ballester M, Bendifallah S, Bolze P-A, Bourdel N, et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF. J Gynecol Obstet Hum Reprod 2020 Jun;49(6):101729.
- [77] Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, et al. Nuclear Medicine Operations in the Times of COVID-19: strategies, Precautions, and Experiences. J Nucl Med 2020;61(5):626. 9J. doi: 10.2967/ jnumed.120.245738.
- [78] Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim J, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo J, Humbert Y, Inoue H, Kauczor F, Luo PJ, Mazzone M, Prokop M, Remy-Jardin L, Richeldi CM, Schaefer-Prokop M, Tomiyama N, Wells AU, Leung AN. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the fleischner society. Radiology 2020. doi: 10.1148/radiol.2020201365.
- [79] Société Française de Radiologie. (2021). https://ebulletin.radiologie.fr/actualitescovid-19/actualisation-recommandations-dimagerie-thoracique-pneumoniecovid-19.